Mosaic ImmunoEngineering, Inc. (CPMV)
Healthcare · PNK
Fundamentals
Valuation and ratings
Mosaic ImmunoEngineering, Inc. trades at USD0.67. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
Our moat model scores it 5 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
CPMV dividend history
No individual payments are on record for this listing, so the current facts above are all we can honestly show.
About Mosaic ImmunoEngineering, Inc.
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on advancing and commercialization of immunotherapies for the treatment of cancer. The company engages in pursuing new product candidates and platforms to build a pipeline based on immunotherapies. Mosaic ImmunoEngineering, Inc. was founded in 2020 and is based in Huntington Beach, California.
CPMV passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
The full research page for CPMV, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.